Institutions / Birchview Capital, LP

Birchview Capital, LP

CIK 1618205 · Institution · as of Dec 31, 2025
Portfolio value
$170.80M
Positions
68
As of
Dec 31, 2025

Top holdings

Dec 31, 2025View all 68 →
CompanyClassValueShares% of portfolio
Kla Corp$26.59M21,88315.6%
Bristol Myers Squibb Co$16.34M302,8429.6%
Compass Therapeutics, Inc.$8.55M1,592,9385.0%
Stoke Therapeutics, Inc.$8.25M260,0004.8%
Lam Research Corp$6.90M40,3294.0%
Olema Pharmaceuticals, Inc.$6.72M269,0003.9%
Structure Therapeutics Inc.GPCRADR$6.26M90,0003.7%
Protagonist Therapeutics Inc$4.80M55,0002.8%
ACADIA Pharmaceuticals Inc$4.57M171,0002.7%
Ovintiv Inc.$4.21M107,5002.5%
Prothena Corp Public Ltd Co$4.21M441,0192.5%
Solid Biosciences Inc.SLDBCommon Stock$3.98M705,9552.3%
Neurocrine Biosciences Inc$3.86M27,1902.3%
Amicus Therapeutics Inc$3.60M253,0002.1%
Bicycle Therapeutics plcBCYCADR$3.28M462,7001.9%
Phathom Pharmaceuticals, Inc.PHATCommon Stock$3.24M195,0001.9%
Castle Biosciences, Inc.$3.14M80,6001.8%
Intellia Therapeutics, Inc.$2.84M315,4001.7%
Immunome Inc.$2.79M130,0001.6%
Corcept Therapeutics Inc$2.34M67,2001.4%
Vera Therapeutics, Inc.$2.23M44,0001.3%
Quidelortho Corp$2.07M72,5481.2%
NovoCure Ltd$1.97M152,1001.2%
Biodesix Inc$1.95M286,8041.1%
Cytokinetics Inc$1.91M30,0001.1%

Activity

Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.